Abstract:
Leflunomide is a commonly used disease modifying antirheumatic agent. However, its use is contraindicated in pregnancy. The American College of Rheumatology (ACR) guidelines recommend discontinuing Leflunomide at least 24 months before conception. If a woman is found to be pregnant while on Leflunomide, ACR suggests close monitoring and cholestyramine washout. We describe a case of a patient with a history of juvenile idiopathic arthritis who was on Leflunomide throughout the first and second trimester of her pregnancy. A cholestyramine washout regimen was started but not completed. The patient was induced at 37 weeks of gestation due to non-reassuring fetal heart rate. She ultimately delivered a healthy baby via emergency cesarian section.
摘要:
来氟米特是一种常用的疾病缓解抗风湿药。然而,它的使用在怀孕中是禁忌的。美国风湿病学会(ACR)指南建议在受孕前至少24个月停用来氟米特。如果发现女性在服用来氟米特时怀孕,ACR建议密切监测和消减胆甾胺。我们描述了一例有幼年特发性关节炎病史的患者,该患者在怀孕的前三个月和第二个三个月都在服用来氟米特。开始了消胆胺清除方案,但未完成。由于胎儿心率不稳定,该患者在妊娠37周时被诱导。她最终通过紧急剖腹产分娩了一个健康的婴儿。